NeuroSTAT® – Treatment for traumatic brain injurY

As things currently stand, there is nothing doctors can do to stop secondary cell death following severe traumatic brain injury. NeuroVive has in-licensed a lipid emulsion and developed NeuroSTAT®, a patented product comprising the active agent cyclosporine-A and a carrier medium which is free from cremophor and alcohol.

Protecting nerve cells

Cyclosporine-A strengthens mitochondrial membranes by binding to and inhibiting the protein cyclophilin-D. This allows the mitochondria to take up and store much more calcium without being damaged, ensuring that they can continue to produce energy and reducing the risk of nerve cell death. The cells of the brain are protected by maintaining their energy supply.

Patent

NeuroVive owns global patent rights for the protection of nerve cells with cyclosporine in cases of acute neurological injury. NeuroVive also holds exclusive patent rights to a cyclosporine-A-based cremophore and ethanol-free lipid emulsion.

Traumatic brain injury

Traumatic brain injuries open the blood-brain barrier. This makes it possible to reach the areas of the brain where the need is greatest by administering cyclosporine-A intravenously to patients.

Immunosuppressive application

As an alternative to existing technology, NeuroSTAT® can also be used to suppress the immune defenses for indications such as organ transplantation.